BioCorRx Adds Former White House Drug Policy Director to Advisory Board

BioCorRx Inc. (OTC: BICX), an addiction treatment solutions company, announced on September 10, 2026, the appointment of Richard J. Baum to its Strategic Advisory Board. Baum is a former Acting Director of the White House Office of National Drug Control Policy (ONDCP) and former Executive Director of the President’s Commission on Combating Drug Addiction and the Opioid Crisis. He brings nearly three decades of experience in national drug policy, addiction, public health, law enforcement, and justice policy.

During 28 years at ONDCP, Baum served across six presidential administrations and helped shape federal responses to evolving drug threats, including the opioid crisis. His experience spans treatment and recovery policy, prevention, public safety, interagency coordination, and collaboration with state and local partners. BioCorRx expects to draw on Baum’s policy and systems-level expertise as the Company advances its treatment and pharmaceutical strategies, including LUCEMYRA® (lofexidine), an FDA-approved non-opioid medication indicated for the mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults, and BICX104, the Company’s investigational biodegradable naltrexone implant technology.

“Rich has spent his career at the intersection of drug policy, public health, treatment, and public safety, and we are honored to welcome him to BioCorRx,” said Lourdes Felix, Chief Executive Officer of BioCorRx Inc. “His deep understanding of how policy translates into real-world treatment access will be invaluable as we work to expand awareness of evidence-based approaches to addiction treatment and thoughtfully position our programs within the broader continuum of care.”

Baum’s perspective will also support the Company’s engagement with treatment and recovery organizations, public health agencies, healthcare systems, justice-system partners, policymakers, and other stakeholders addressing substance use, withdrawal management, and related public health challenges.

“I am pleased to join BioCorRx as a strategic advisor at a time when the country continues to face significant challenges related to opioid use, addiction treatment, and recovery,” said Richard J. Baum. “BioCorRx is working across several important points in the treatment continuum, including managing opioid withdrawal symptoms with LUCEMYRA. In an era of increasingly dangerous polysubstance use, particularly involving illicit fentanyl and methamphetamine, I am also encouraged by the Company’s research evaluating BICX104, an investigational long-duration naltrexone implantable pellet, as a potential treatment for methamphetamine use disorder. I look forward to helping BioCorRx position these approaches within a comprehensive, evidence-based system of care that expands treatment access, supports retention, and improves long-term recovery.”

Baum is a nationally recognized drug policy leader, author, educator, speaker, and strategic advisor. He is an Adjunct Professor at Georgetown University’s McCourt School of Public Policy and the author of Inside America’s Opioid Crisis: 12 Hard Lessons for Today’s Drug War. He also serves on the United Against Fentanyl Board of Directors. His recent writing on the opioid crisis has appeared in The Lancet.

The appointment comes as the nation continues to grapple with substance use disorders. According to the 2025 National Survey on Drug Use and Health, an estimated 4.0 million people in the United States aged 12 or older had an opioid use disorder in the past year. Approximately 2.7 million people reported using methamphetamine in the past year, while over 15 million have used methamphetamine at least once in their lifetime.

BioCorRx Inc. is an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders. Its Beat Addiction Recovery program typically includes proprietary Cognitive Behavioral Therapy (CBT) modules along with peer support via mobile app and medication prescribed by an independent treating physician. The UnCraveRx® Weight Loss Program is a medication-assisted weight loss program that includes access to concierge on-demand wellness specialists. For more information, visit www.uncraverx.com. BioCorRx also operates through its subsidiary, BioCorRx Pharmaceuticals Inc., which focuses on pharmaceutical commercialization and development. For more information, visit www.BioCorRx.com.

LUCEMYRA® (lofexidine) is an oral tablet indicated for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults. It is not a treatment for opioid use disorder. BICX104 is BioCorRx’s investigational biodegradable naltrexone implant technology designed to provide controlled delivery of naltrexone. A new clinical study evaluating BICX104 commenced in January 2026 (ClinicalTrials.gov Identifier: NCT07269873), with additional studies planned. The current clinical study is supported by the National Institute on Drug Abuse (NIDA) of the National Institutes of Health under Award Number U01DA059994.

Baum’s appointment could bolster BioCorRx’s efforts to expand access to evidence-based addiction treatment and to position its pipeline within a comprehensive system of care. For Texas and the broader business community, the move signals a growing focus on addressing substance use disorders, which impose significant costs on healthcare systems, employers, and communities. As the opioid crisis persists, strategic hires like Baum may help bridge the gap between policy and practical treatment solutions, potentially improving outcomes and reducing economic burdens.